US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Schizophrenia · Autosomal Recessive Polycystic Kidney Disease
Otsuka Beijing Research
Otsuka Beijing Research Institute
Otsuka Beijing Research drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 33
- Drugs
- 25
- Patents
- 0
Otsuka Beijing Research pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Otsuka Beijing Research drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
aripiprazole
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
- Target
- cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
- Mechanism
- Phosphodiesterase 3A inhibitor
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
delamanid
Antiinfectives for systemic use (J04)Antiinfectives for systemic use (J04) compound in Otsuka Beijing Research's portfolio. Molecular target: Mycobacterium tuberculosis H37Rv.
- Target
- Mycobacterium tuberculosis H37Rv
- Mechanism
- Mycobacterium tuberculosis H37Rv inhibitor
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Various (V04) compound in Otsuka Beijing Research's portfolio.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.
-
tolvaptan
Cardiovascular system (C03)US regulatory status: approved. Molecular target: Vasopressin V2 receptor.
- Target
- Vasopressin V2 receptor
- Mechanism
- Vasopressin V2 receptor antagonist
-
Development asset linked to Otsuka Beijing Research in public FDA and regional records.